A methanol extract of the seed of Prunus persica (Rosaceae) was found to inhibit histamine release in human mast cells. Activity-guided fractionation of the methanol extract yielded three cyanogenic glycosides (1-3) and other phenolic compounds (4-8). To evaluate their anti-allergic and anti-inflammatory activities, the isolates (1-8) were tested for their inhibitory effects on histamine release and on the gene expressions of tumor necrosis factor (TNF)-α and interleukin (IL)-6 in human mast cells. Of these, phenolic glycosides 7 and 8 suppressed histamine release and inhibited the pro-inflammatory cytokines TNF-α and IL-6. These results suggest that isolates from P. persica are among the anti-allergic inflammatory principles in this medicinal plant.
Allergic inflammation affects target cells, such as epithelial, fibroblast, vascular, and airway smooth muscle cells, which become an important source of inflammatory mediators [1a] . Mast cells appear to play a critical role in initiating allergic inflammation, since they are directly activated by allergens via an immunoglobulin E (IgE)-dependent mechanism [1a,1b] . Activated mast cells lead to degranulated histamine, and release of pro-inflammatory and chemotactic cytokines [1b] . Several proinflammatory cytokines have been implicated in allergic diseases, including interleukin (IL)-1β, IL-6, TNF (tumor necrosis factor)-α, and granulocytemacrophage colony-stimulating factor (GM-CSF), and these may be important for amplifying allergic inflammatory responses [1a,1b] .
Prunus persica (L.) Batsch (Rosaceae) is a deciduous tree that bears an edible fruit. Its seeds are used in traditional medicine to treat amenorrhea and rheumatoid arthritis [2a] . Phytochemical studies on this plant have reported various cyanogenic glycosides, glycerides, sterols, and fatty acids [2b-2d] . Furthermore, pharmacological studies on the seeds of P. persica have shown they have multiple activities, which include anti-cancer, anti-oxidant, hepatoprotective, antinociceptive, and anti-coagulant, and inhibitory effects on platelet aggregation [2d-2f] . In a previous study, we described the anti-allergic inflammatory effect of the ethanol extract of fruits of P. persica in human mast cells [3] . Activity-guided fractionation of the methanol extract led to the isolation of three cyanogenic glycosides, prunasin (1), amygdalin (2), neoamygdalin (3) and five phenolic compounds, dehydroconiferyl alcohol (4), dehydroconiferyl alcohol-4'-O-β-D-glucopyranoside (5), dehydroconiferyl alcohol-10-O-β-D-glucopyranoside (6), vanilloloside (7) and lacticolorin (8). Compounds 5, 7 and 8 were isolated for the first time from this plant.
It is known that the inhibitory effect of mast cells on histamine release plays an important role in the anti-allergic effect [1a] . Therefore, we examined in vitro histamine release inhibitory activity using assays of compound 48/80-induced histamine release from human mast cells and pro-inflammatory cytokines inhibitory activity. As shown in Figure 2 , compared with the phorbol-12-myristate 13-acetate plus calcium ionophore A23187 (PMACI) control, compounds 4, 5, 7 and 8 significantly inhibited histamine release and pro-inflammatory cytokines.
Experimental
Plant material: Seeds of Prunus persica were purchased from Yak-Ryung-si market in Daegu, Korea and were identified by Dr Seung Ho Lee at the College of Pharmacy, Yeungnam University. A voucher specimen (YU00163) has been deposited in the Natural Product Laboratory at the College of Pharmacy, Yeungnam University, Korea.
Extraction and isolation:
The seeds of P. persica (1.2 kg) were pulverized and extracted with MeOH (5.0 L × 3) for one week at room temperature. The solution was evaporated to dryness to obtain 85.0 g of extract. This was loaded onto a silica gel column and eluted with a step-wise gradient mixture of ethyl acetate (EtOAc) and MeOH (1:0 to 0:1) to yield 13 sub-fractions (Fr.3-1 ~ Fr.3-9). Fr.3 (678.7 mg) was further divided into 9 subfractions (Fr.1-1 ~ Fr.1-9) using silica gel chromatography and eluting with a step-wise gradient mixture of methylene chloride (MC) and acetone (100:0 to 40:60). Fr.3-5 (75.9 mg) was purified by preparative HPLC (MeOH-H 2 O, 3:7 to 7:3; 6 mL/min) to afford (-) dehydroconiferyl alcohol (4) (t R 29.8 min, 4.5 mg) [4a] . Fr.4 (8.5 g) was loaded onto silica gel and eluted with a mixture of MC and MeOH (100:0 to 85:15) to yield 6 sub-fractions (Fr.4-1 ~ Fr.4-6). Purification of Fr.4-2 (113.5 mg) using preparative HPLC (MeOH-H 2 O, 40:60 to 65:35; 6 mL/min) yielded (-) lacticolorin (8) (t R 37.4 min, 3.0 mg) [4f]. Fr.5 (2.1 g) was separated on silica gel using a gradient mixture of MC and MeOH (10:0 to 5:5) to afford 9 subfractions (Fr.5-1 ~ Fr.5-9). Fr.5-7 (139.9 mg) was further purified by preparative HPLC with a gradient mixture of MeOH and H 2 O (from 1:9 to 5:5, 6 mL/min) to afford (+) neoamygdalin (3, t R 23.2 min 69.4 mg) [4b]. Fr.5-8 (755.5 mg) was also purified by preparative HPLC (MeOH-H 2 O, 3:7 to 4:6; 6 mL/min) to give (-) dehydroconiferyl alcohol-10-O-β-D-glucopyranoside (6, t R 30.8 min, 1.2 mg) [4d]. Fr.6 (15.2 g) was subjected to silica gel vacuum liquid chromatography, and eluted with a gradient mixture of CHCl 3 /MeOH/H 2 O [9:1:0.05, 9:1.5:0.05, 9:2:0.1, 9:3:0.1, 0:10:0 (each 2 L)] to yield (-) amygdalin (2, 3.0 g) [4b] and 4 sub-fractions (Fr.6-1 ~ Fr.6-4). Fr.6-3 was fractionated by silica gel chromatography using a gradient of CHCl 3 and MeOH (10:0 to 7:3) to yield (-) prunasin (1, 50.0 mg) [4b] and 7 sub-fractions (Fr.6-3-1 ~ Fr.6-3-7). Fr.6-3-7 (458.6 mg) was further purified by preparative HPLC (MeOH-H 2 O, 1:9 to 6:4; 6 mL/min) to afford (-) vanilloside (7, t R 27.9 min, 5.7 mg) [4e] and (-) dehydroconiferyl alcohol-4'-Oβ-D-glucopyranoside (5, t R 57.9 min, 21.2 mg) [4c].
Histamine assay: The histamine content was measured by the o-phthaldialdehyde spectrofluorometric procedure, as previously described [1b] . The serum was separated from the released histamine by centrifugation at 400 × g for 5 min at 4°C. The fluorescent intensity was measured at an excitation wavelength of 355 nm and an emission wavelength of 450 nm using a Perkin-Elmer Fluorescence Spectrometer LS-50B (Norwalk, CT, USA).
Real-time polymerase chain reaction (PCR):
Quantitative real-time PCR was carried out using the Thermal Cycler Dice TP850 (Takarabio Inc., Shiga, Japan) according to the manufacturer's protocol. Total RNA was isolated from ear tissues of each group. The conditions for PCR were similar to those previously described. Briefly, 2 μL of cDNA (100 ng), 1 μL of sense and antisense primer solution (0.4 μM), 12.5 μL of SYBR Premix Ex Taq (Takarabio Inc.), and 9.5 μL of D 2 O were mixed together to obtain a final 25 μL reaction mixture in each reaction tube. The primers used for PCR were (IL-6 F 5'-AAAGAGGCACTGGCAGAAAA, R 5'-ATCTGAGGTGCCCATGCTAC, TNF-α F 5'-CCTGTAG CCCACGTCGTAGC, R 5'-TTGACCTCAGCGCTGAGTTG). The amplification conditions were 10 s at 95°C, 40 cycles of 5 s at 95°C and 30 s at 60°C, 15 s at 95°C, 30 s at 60°C, and 15 s at 95°C. The normalization and quantification of mRNA expression was performed using the TP850 software supplied by the manufacturer.
Statistical analysis:
Statistical analyses were performed using SAS statistical software (SAS Institute, Cary, NC, USA). Treatment effects were analyzed using ANOVA followed by Dunnett's multiple range tests. Significance was set at P < 0.05.
